Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed + Cisplatin vs Cisplatin in Recurrent/Metastatic Head and Neck Cancer
NCT00415194Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2006
- Primary completion
- Mar 2010
- Modality
- Small Molecules
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing Pemetrexed/Cisplatin with Placebo/Cisplatin (2 arms). Primary endpoint: Overall Survival at 36 months. Started Dec 2006; status: completed.
02
Drugs
pemetrexed
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT00415194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00415194.